Equities Analysts Set Expectations for Eli Lilly and Company’s Q1 2026 Earnings (NYSE:LLY)

Eli Lilly and Company (NYSE:LLYFree Report) – Zacks Research raised their Q1 2026 EPS estimates for Eli Lilly and Company in a report issued on Monday, April 1st. Zacks Research analyst K. Shah now expects that the company will post earnings per share of $6.11 for the quarter, up from their prior estimate of $6.09. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.42 per share. Zacks Research also issued estimates for Eli Lilly and Company’s FY2026 earnings at $24.70 EPS.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $2.09 EPS.

A number of other research analysts also recently issued reports on the stock. Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $700.00.

Read Our Latest Report on LLY

Eli Lilly and Company Trading Up 0.4 %

Shares of NYSE LLY traded up $3.41 during midday trading on Tuesday, reaching $763.96. The stock had a trading volume of 2,552,910 shares, compared to its average volume of 3,220,474. The firm has a market cap of $725.88 billion, a price-to-earnings ratio of 131.72, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $342.30 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company’s 50 day moving average price is $739.63 and its 200 day moving average price is $641.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $26,000. Core Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $27,000. Tidemark LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Finally, Retirement Group LLC boosted its stake in Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the sale, the insider now owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 195,055 shares of company stock valued at $125,254,657 over the last ninety days. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Earnings History and Estimates for Eli Lilly and Company (NYSE:LLY)

Before you consider Eli Lilly and Company, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Eli Lilly and Company wasn’t on the list.

While Eli Lilly and Company currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report


Source link

Check Also

Allworth Financial LP Raises Stock Position in Alexandria Real Estate Equities, Inc. (NYSE:ARE)

Allworth Financial LP increased its stake in Alexandria Real Estate Equities, Inc. (NYSE:ARE – Free …

Leave a Reply

Your email address will not be published. Required fields are marked *